UNSPSC 51434007: Bepridil hydrochloride monohydrate

This classification denotes a calcium channel blocker with the molecular formula C24H34N2O.ClH.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4W2P15D93M, chemically known as 1-(2-(n-benzylanilino)-1-(isobutoxymethyl)ethyl)-pyrrolidine monohydrochloride monohydrate, but more generally known as bepridil hydrochloride monohydrate, which bears US NIH Compound Identifier 91725.

European Medicines Agency schedules bepridil hydrochloride monohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB13041MIG. Most nations, for tariff purposes, schedule bepridil hydrochloride monohydrate under HS 29339990. SMILES: CC(C)COCC(CN(CC1CCCCC1)C2CCCCC2)N3CCCC3.O.CL.

UNSPSC 51434007 Bepridil hydrochloride monohydrate is a Commodity code representing specific pharmaceutical active ingredients procured by state and local health agencies. Recent state and local opportunities under this code show that governments buy advanced life support medications and generic multi-source pharmaceuticals for emergency medical services, hospital systems, and state health benefit programs. The City of Tampa's fire rescue division, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) all solicit under related pharmaceutical procurement codes, indicating that issuing bodies span municipal emergency services departments, state health agencies, and cooperative purchasing alliances serving multiple jurisdictions. The work involves supplying FDA-compliant medications with specified expiration dates, maintaining cold-chain or storage integrity, arranging delivery within tight windows, and providing full compliance documentation including Safety Data Sheets, manufacturing certifications, and accessibility reporting.

Recent activity clusters in Florida, Texas, and Minnesota. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications due April 8, 2026, with an estimated contract value of $40,000 and a one-year term plus renewal options; the solicitation includes a 5 percent bid discount for Small Local Business Enterprise participation and requires delivery within ten calendar days. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, as a preliminary market-intelligence gathering effort for direct-to-manufacturer prescription programs serving state employee and retiree health plans—an exploratory phase with no immediate award but signaling future RFP intent. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued RFP S1070000015802 with a March 26, 2026 response deadline for generic multi-source pharmaceuticals and OTC products to serve participating state and local government facilities in Minnesota, Oregon, and other alliance member jurisdictions; the RFP emphasizes price competitiveness (75 percent weight), requires cGMP and Drug Supply Chain Security Act compliance, and specifies a two-year contract term with a 3 percent administrative fee on all purchases.